We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $152.42, demonstrating a +1.68% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.05% for the day. Meanwhile, the Dow gained 0.69%, and the Nasdaq, a tech-heavy index, added 1.64%.
Heading into today, shares of the kidney dialysis provider had lost 2.21% over the past month, lagging the Medical sector's gain of 0.31% and the S&P 500's gain of 8.59%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is scheduled to release its earnings on May 5, 2026. In that report, analysts expect DaVita HealthCare to post earnings of $2.41 per share. This would mark year-over-year growth of 20.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.3 billion, up 2.36% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $14.16 per share and a revenue of $14.11 billion, demonstrating changes of +31.35% and +3.41%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 10.59. This indicates a discount in contrast to its industry's Forward P/E of 18.37.
It is also worth noting that DVA currently has a PEG ratio of 0.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.68 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $152.42, demonstrating a +1.68% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.05% for the day. Meanwhile, the Dow gained 0.69%, and the Nasdaq, a tech-heavy index, added 1.64%.
Heading into today, shares of the kidney dialysis provider had lost 2.21% over the past month, lagging the Medical sector's gain of 0.31% and the S&P 500's gain of 8.59%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is scheduled to release its earnings on May 5, 2026. In that report, analysts expect DaVita HealthCare to post earnings of $2.41 per share. This would mark year-over-year growth of 20.5%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.3 billion, up 2.36% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $14.16 per share and a revenue of $14.11 billion, demonstrating changes of +31.35% and +3.41%, respectively, from the preceding year.
Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, DaVita HealthCare holds a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 10.59. This indicates a discount in contrast to its industry's Forward P/E of 18.37.
It is also worth noting that DVA currently has a PEG ratio of 0.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.68 as trading concluded yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 148, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.